A
Axel Ullrich
Researcher at Max Planck Society
Publications - 436
Citations - 63142
Axel Ullrich is an academic researcher from Max Planck Society. The author has contributed to research in topics: Receptor tyrosine kinase & Tyrosine kinase. The author has an hindex of 124, co-authored 436 publications receiving 61445 citations. Previous affiliations of Axel Ullrich include Institute of Molecular and Cell Biology & Agency for Science, Technology and Research.
Papers
More filters
Journal ArticleDOI
FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer
Christoph Thussbas,Jörg Nährig,Sylvia Streit,Johannes Bange,Monika Kriner,Ronald E. Kates,Kurt Ulm,Marion Kiechle,Heinz Hoefler,Axel Ullrich,Nadia Harbeck +10 more
TL;DR: The results show that the previously found association of FGFR4 Arg388 genotype with breast cancer progression is strongest in patients with adjuvant systemic therapy, particularly chemotherapy, and thus may reflect therapy resistance.
Journal ArticleDOI
Characterization and comparison of four serine- and arginine-rich (SR) protein kinases.
TL;DR: It is demonstrated that all variants of mclk1/STY encode autophosphorylating proteins that can phosphorylate several biochemically purified SR proteins in vitro, leading to hyperphosphorylation of at least one SR protein in vivo.
Journal ArticleDOI
Characterization of an endogenous substrate of the insulin receptor in cultured cells
TL;DR: The notion that the insulin signal may be transmitted to a cellular substrate (pp185) which may initiate insulin action at intracellular sites is supported.
Journal ArticleDOI
Evidence for epidermal growth factor (EGF)-induced intermolecular autophosphorylation of the EGF receptors in living cells.
TL;DR: It appears, therefore, that crucial events of signal transduction occur before K721A and active EGF receptors are separated by their different endocytic itineraries.
Journal Article
Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
Laura K. Shawver,D P Schwartz,E Mann,Hui Chen,J Tsai,L M Chu,L Taylorson,Michael P. Longhi,Stephen C. Meredith,L L Germain,J S Jacobs,C. Tang,Axel Ullrich,Michael E. Berens,Evan M. Hersh,Gerald McMahon,K. P. Hirth,T. J. Powell +17 more
TL;DR: SU101 is an effective inhibitor of PDGF-driven tumor growth in vivo and prevents tumor growth and induced long-term survivors in animals implanted with 7TD1 (murine B-cell hybridoma) tumor cells.